We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

PERKIN ELMER CORPORATION

PerkinElmer provides detection technologies to detect and identify diseases, imaging technologies to help visualize s... read more Featured Products: More products

Download Mobile App





PerkinElmer’s EUROIMMUN Launches Novel ELISA for Detection of SARS-CoV-2 Antigen in Acutely Infected Patients

By LabMedica International staff writers
Posted on 17 Dec 2020
Print article
Image: SARS-CoV-2 Antigen ELISA (Photo courtesy of EUROIMMUN)
Image: SARS-CoV-2 Antigen ELISA (Photo courtesy of EUROIMMUN)
EUROIMMUN, a PerkinElmer, Inc. (Waltham, MA; USA) company, has launched the CE marked SARS-CoV-2 Antigen ELISA for specific determination of the SARS-CoV-2 protein.

The Antigen ELISA is a laboratory test able to be applied in semi quantitative automatable detection of the SARS-CoV-2 nucleocapsid protein on a large scale. It is validated for swab sample material from the upper respiratory tract and is useful for testing individuals with acute symptoms that point to COVID-19 or who have had suspected contact with SARS-CoV-2. Validation data revealed 93.6% positive agreement (sensitivity) and 100% negative agreement (specificity) between results obtained with the Antigen ELISA and those obtained with a real time PCR test for detecting the virus. Based on the well-known ELISA technology, the SARS-CoV-2 Antigen assay can be performed in most diagnostic laboratory settings and automatically processed on all open ELISA platforms.

The SARS-CoV-2 Antigen ELISA is available in countries that recognize CE marking. Validation of saliva specimens for use with this assay is currently in process. The assay is the latest of the comprehensive EUROIMMUN COVID-19 product portfolio and the third test to support acute COVID-19 diagnostics following the two molecular diagnostic systems: EURORealTime SARS-CoV-2 and EURORealTime SARS-CoV-2/Influenza A/B.

“Infection numbers are continuously increasing, and there is enormous pressure to provide sufficient test capacities. The availability of gold-standard PCR testing, however, is often challenged in acute COVID-19 outbreak situations. That’s why a reliable and automatable antigen detection test as our new ELISA can be a valuable supplement to help rapid identification of acutely infected individuals,” said Dr. Wolfgang Schlumberger, CEO of EUROIMMUN.


New
Gold Supplier
Cytocentrifuge
Cytopro Cytocentrifuge Series 2
COVID-19 IgM/IgG Test
DPP COVID-19 IgM/IgG System
New
Gold Supplier
Clinical Chemistry Series
Clinical Chemistry Series
DNA/RNA Extraction Kit
Exiprep 96 Lite & Viral DNA/RNA Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: Micrograph of a colorectal adenocarcinoma (Photo courtesy of Wikimedia Commons)

Plasma or Urine Liquid Biopsy Tests May Guide Colorectal Cancer Treatment

A recent paper suggested that liquid biopsy examination of blood or urine could aid in evaluating the effectiveness of therapy for colorectal cancers that had begun to metastasize beyond the site of the... Read more

Industry

view channel
Image: Sysmex CN-Series automated blood coagulation analyzer (Photo courtesy of Sysmex Corporation)

Siemens and Sysmex Extend Agreement to Provide One of the Largest Portfolios of Hemostasis Testing Systems and Reagents

Siemens Healthineers (Erlangen, Germany) and Sysmex Corporation (Kobe, Japan) have renewed their long-standing global supply, distributorship, sales and service agreement for a broad portfolio of hemostasis... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.